Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000037606 | SCV000061267 | uncertain significance | not specified | 2010-11-05 | criteria provided, single submitter | clinical testing | Variant classified as Uncertain Significance - Favor Benign. The Tyr375Cys varia nt in PTPN11 has not previously been reported in the literature or been observed identified in our laboratory, although it is listed in dbSNP (rs41299183, not v alidated). Tyrosine (Tyr) at amino acid position 375 is not highly conserved in different species, and two different computational analyses predict this variant to have a benign effect on the function of the protein. However, in the absence of additional data, the clinical significance of this variant cannot be determi ned at this time. |
Labcorp Genetics |
RCV001042982 | SCV001206692 | uncertain significance | RASopathy | 2023-12-11 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 375 of the PTPN11 protein (p.Tyr375Cys). This variant is present in population databases (rs41299183, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with PTPN11-related conditions. ClinVar contains an entry for this variant (Variation ID: 40544). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PTPN11 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002477047 | SCV002778713 | uncertain significance | Noonan syndrome 1; Juvenile myelomonocytic leukemia; Metachondromatosis; LEOPARD syndrome 1 | 2021-10-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004017275 | SCV004849255 | uncertain significance | Cardiovascular phenotype | 2019-04-05 | criteria provided, single submitter | clinical testing | The c.1124A>G (p.Y375C) alteration is located in exon 10 (coding exon 10) of the PTPN11 gene. This alteration results from a A to G substitution at nucleotide position 1124, causing the tyrosine (Y) at amino acid position 375 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |